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AMIODARONE-INDUCED PHLEBITIS
Abstract

Amiodarone is used in the management of ventricular and atrial arrhythmias, and the drug of
choice among many cardiothoracic surgeons to manage post-operative arrhythmias. Atrial
fibrillation with rapid ventricular response, is the most common arrhythmia treated with
amiodarone in a telemetry unit in one medical center located in northern California. Nurses have
noted a high incidence rate of phlebitis related to amiodarone infusion even when the current
hospital guidelines are being followed. Data were collected over six months and included 35
patients, each infusion via a different intravenous site was considered another occurrence, for a
total of 40 infusions. There were 16 cases of phlebitis that developed which was a 40% incidence
rate. Some patients had more than one episode of phlebitis. A multidisciplinary team was formed
to introduce practice change. Interventions focused on education of staff and implementation of
evidence-based practice guidelines for infusion. Data collection of phlebitis incidence was
performed post-intervention over four weeks that included 4 patients with a total of 7 infusions.
Each infusion was considered as a separate occurrence. There were 3 cases of phlebitis, with one
patient accounting for two cases. The result is a 43% incidence rate of phlebitis. A follow-up
study is necessary after six-months of data collection post-intervention in order to make a more
balanced analysis of the result, and this continuation of data collection is in progress.

Keywords: Amiodarone, phlebitis, guideline, side effects, infusion, thrombophlebitis.
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Amiodarone-Induced Peripheral Phlebitis: Implementation of Practice Guideline to Decrease
Incidence

Problem Description

Managing arrhythmias in a cardiac unit can pose a significant challenge for nurses and
physicians in their daily practice. The life-threatening nature of the problem makes it critical to
have a drug that can be infused readily and can manage the arrhythmias effectively. First
discovered in 1961, Amiodarone is a Vaughan Williams class III anti-arrhythmic drug
commonly used in the setting of managing unstable atrial and ventricular arrhythmias (Brady
Boyce & Homer Yee, 2012). Approved by the Food and Drug Administration (FDA) in 1985,
the increased use of amiodarone has also been linked to phlebitis. The approval of the FDA is
limited to the treatment of ventricular fibrillation and ventricular tachycardia. However, the offlabel use of amiodarone in managing atrial arrhythmias, such as atrial fibrillation in the
postoperative period, has gained popularity among cardiac surgeons, (Hannibal, 2016).
Endorsed by consensus guidelines published by the American College of Cardiology
(ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC)
in the treatment of atrial fibrillation, the guidelines also acknowledge that one of the common
side effects when infused peripherally is phlebitis (Spiering, 2014). With its increased use in
many cardiac-care units, a high incidence of amiodarone-related phlebitis has also been noted,
prompting three major nursing journals in the last few years to address this issue (Hannibal,
2016). With an increasing number of patients presenting for hospital admission with atrial
fibrillation, or having atrial fibrillation post-cardiac surgery, combined with the drive to manage
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atrial arrhythmias to avoid complications such as stroke, the likelihood that healthcare
institutions will continue to use amiodarone to manage such diagnoses is high.
Phlebitis is defined as an inflammation of the vein wall characterized by pain, edema,
erythema, streak formation and/or a palpable cord (Washington & Barrett, 2012). The Infusion
Nurses Society (INS) phlebitis scale is widely used in the clinical setting to grade the severity of
phlebitis, in a range from 0 to 4, with 4 being the most severe. An additional phlebitis scale; the
visual phlebitis scale is another alternative assessment tool widely used in grading the severity of
phlebitis (see appendix A for both phlebitis scales). According to INS (2011), the rate of
phlebitis should be 5% or less in any given population of patients receiving peripheral infusions.
The 2016 INS Intravenous Therapy Standards of Practice identified four categories of phlebitis:
chemical, mechanical, bacterial, and phlebitis driven by patient characteristics. The INS also
acknowledged post-infusion phlebitis that can develop due to any of the same causes.
Amiodarone-related phlebitis, in particular, can be categorized under chemical phlebitis. The
chemical features of amiodarone, such as its acidity, have been thought to be a major culprit in
phlebitis formation with amiodarone infusion (Spiering, 2014).

It has been noted that there is a direct connection between pH and osmolarity of an
infusate contributing to phlebitis formation. In the case of amiodarone, it is hypothesized that the
acidic pH level (ranging from 3.4-4.5 in some literature) is more responsible for phlebitis rather
than the osmolarity (Spiering, 2014). Pharmaceutical companies are well aware of the
complication of phlebitis when amiodarone is infused peripherally. Information on how to avoid
phlebitis is included in the prescribing information from the various manufacturers, and has
included recommendations for using an in-line filter to reduce particulate formation, use of
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central venous catheter for infusions longer than one hour, and if the drug concentration is 2
milligram(mg)/ milliliter (ml) and higher (Baxter Healthcare Corporation, 2018). Ideally, it is
recommended that all infusions should be given via central venous catheter due to phlebitis as a
known side effect. However, this is not always feasible since intravenous amiodarone is usually
prescribed during emergencies or when patients develop arrhythmias where timing is not always
predictable. In many cases, a central line is not always readily available for all patients.

In addition to pH and osmolarity contributing to phlebitis, the preservatives added to
amiodarone and the drug’s inherent tendency to precipitate when it enters the blood stream have
also been hypothesized as causative factors. The conventional amiodarone preparation contains
preservatives such as polysorbate 80 and benzyl alcohol, both thought to contribute to phlebitis
formation. Some pharmaceutical companies have done their best to eliminate such preservatives
in their packaging. With regard to precipitation of amiodarone once diluted or in contact with the
bloodstream, a study by Ward and Yalkowsky (1993) using animal subjects found that rapidly
forming needle-shaped crystals adhere to the intima of the vein causing trauma to the vascular
endothelium when amiodarone is infused. Smaller volume infusions did not illicit the same
inflammatory response, but as the volume of amiodarone infused increased, so did the severity of
thrombophlebitis. It is then hypothesized that even when the amiodarone infusion was diluted,
the amount of precipitation still exceeded the solubility of the drug in the bloodstream (Mowry &
Hartman, 2011).

Phlebitis has been well-known as a side effect of amiodarone infusion for many years and
thus, hospitals across the country have conducted studies to improve practice and minimize it. In
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2014, Spiering, a cardiology clinical nurse specialist at Providence Saint Vincent Medical Center
in Oregon at the time, conducted a study and published the results in the Journal of Infusion
Nursing. The study found that the implementation of amiodarone peripheral infusion guidelines
significantly decreased the incidence rate of phlebitis from 85% pre-guidelines down to 38%
post-guidelines, representing a 47% improvement. It also showed reduced severity of phlebitis
after the guidelines were implemented. The study was conducted in response to nurses reporting
a high incidence of phlebitis in a telemetry unit, causing pain and infection in patients, and often
delaying discharge. There were no existing guidelines for amiodarone infusion at the facility
before the study. Study patients were identified from those admitted to a single institution, using
an observational convenience sample consisting of 34 patients over a six-month period. A multidisciplinary team was formed including nurses, cardiologists, pharmacists, and the intravenous
(IV) therapy team, and an approval from the Institutional Review Board (IRB) was obtained.
Multiple peer-reviewed research articles were used in the development of the guidelines.
The effective guidelines included use of dedicated lines, separate filters for boluses and
infusions, patient instruction to notify a nurse immediately in case of pain or redness at the site,
inspection of the IV site during change of shift report, and discontinuation of catheter at the first
sign of pain and redness. Although the guidelines appear to be successful in decreasing the
incidence of amiodarone-related phlebitis, the sample size was small and the population used
were strictly adult cardiac patients. Therefore, the study may not be generalizable to the rest of
the hospital population. There is also a question of whether or not the decrease in phlebitis can be
attributed to the guideline themselves, or was merely a response to an increased awareness and
understanding of amiodarone complications on the part of staff.
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In a study published in Critical Care Journal, Brady Boyce & Homer Yee (2012)
conducted a study to determine the rate and severity of phlebitis related to peripheral infusion of
amiodarone and to evaluate the magnitude of the problem at Mount Auburn Hospital in
Massachusetts. Nurses were reporting a high incidence of phlebitis even when existing
guidelines for drug administration was being followed. Those guidelines included having
amiodarone prepared in a glass bottle from pharmacy, and the use of an in-line filter in case of
drug precipitation. The study included a review of the current literature and of the hospital’s
current policy and procedures. The hospital’s IRB was consulted, and a multidisciplinary team
was formed including nurses, an IV therapy nurse, a cardiovascular nurse specialist, a
pharmacist, and a research advisor.
Using a descriptive design, data was collected over a six-month period using a
convenience sampling of 12 patients. Each infusion of amiodarone was treated as a separate
occurrence, for a total of 24 infusions. A collection tool drafted by the multi-disciplinary team
was used to aid in determining variables that would affect phlebitis development. This tool was
then submitted and reviewed by the nursing research council prior to its use and face validation
was established. The study was stopped after six months due a high rate of phlebitis, and a plan
for action to prevent further harm to patients was initiated immediately. The study showed
various grades of phlebitis developed in eight patients (67%), and phlebitis developed at 12 of
the 24 infusion sites (50%). This was a far higher rate than that reported in the literature, which is
between 7-23% (Brady Boyce & Homer Yee, 2012). The high rate of phlebitis warranted a plan
to increase awareness and education for nurses and other medical staff, as well as a change in the
policy and practice guidelines and subsequent implementation of those changes.

AMIODARONE-INDUCED PHLEBITIS

8

These changes to practice included involvement of the IV therapy nurse to monitor
infusion sites, annual competency testing for nurses regarding amiodarone infusion, increasing
the frequency of IV site assessment, use of in-line filters during infusion, and reminding
physicians about the risk of phlebitis associated with amiodarone infusion to alert them to
carefully consider the length of infusion and possible conversion to oral route of administration.
The small sample size was identified as one of the limitations of the study, although it was
enough to make changes to policy and practice guidelines promptly. The result, even from a
small sample, combined with the known common side effect of amiodarone, triggered the
appropriate response by the medical center to consider patient safety as their top priority. There
is, however, no outcome study or follow up data mentioned in the study to determine whether the
changes made decreased the incidence of phlebitis at this facility.
Another study published in American Journal of Critical Care by Norton, et al. (2013) at
Stanford University in California, examined the magnitude of the problem of amiodarone-related
phlebitis in a critical care unit (CCU). Staff recognized the problems of amiodarone-related
phlebitis when infused peripherally even when the current recommendations of drug
administration were being followed. The current protocol of the facility at the time of the study
called for use of an in-line filter, central line for higher concentration of the drug, and only used
peripheral lines for lower drug concentrations. The guidelines were insufficient as evidenced by
the high incidence of phlebitis and the need for refinement was recognized.
A retrospective descriptive study over an 18-month period was conducted with a total
sample of 105 patients. The study found the incidence of phlebitis to be 40% with a 50%
recurrence rate. All cases of phlebitis occurred in patients who received a total dose of 3 grams
peripherally, and one quarter of the cases developed phlebitis at dosages less than 1 gram per
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dose, with complications occurring within 24 hours of treatment (Norton, et al., 2013). Results of
the study clearly warranted a change in practice policy which included continuing use of an inline filter, using the largest peripheral vein for infusion, converting to oral dosing within 24
hours of IV administration, insertion of percutaneous central catheter if infusion exceeded 24
hours, creation of pharmacy order set, and mandatory assessment of the IV site by nurses. The
study emphasized that an outcome study would be needed to measure the effectiveness of the
changes adopted in their practice policy.

Rationale
Intravenous amiodarone is widely used in the management of rapid control of arrhythmias in the
author’s microsystem, a telemetry unit located in northern California. The high utilization of
intravenous amiodarone in the management of arrhythmias has brought attention to an
accompanying high rate of phlebitis related to the infusion. The author tracked and collected data in
collaboration with charge nurses in her unit and has shown a 40% incidence rate over a six-month
period in 35 patients with repeat occurrence of phlebitis in some. A total of 40 infusions resulted in
16 case of phlebitis. The high incidence rate of phlebitis has caused pain and discomfort to patients,
extending hospital length of stay (LOS), thereby, increasing cost, and contributes to lower score on
patient satisfaction survey. According to HealthCare.gov (2018), the average cost of a three-day
hospital stay is around $30,000. Prolonged length of hospital stay due to phlebitis complication can
significantly contribute to high cost in healthcare expenditure. In severe cases, sepsis can develop,
further extending length of hospital stay and causes suffering of patient.
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Currently, the only practice guidelines at the author’s microsystem are the use of a 0.22

micron in-line filter when administering amiodarone, and the mandatory use of central lines for
infusions of concentrations exceeding 2 mg/ml. In addition, there is no available policy and
procedure related to amiodarone infusion with regard to management of intravenous
complications, such as phlebitis and medication extravasation. The hospital currently uses premixed amiodarone intravenous bags from the hospital’s chosen pharmaceutical supplier with a
concentration of 0.5 mg/mL for intravenous bolus, and 1.8mg/ml for continuous infusion. The
ongoing high incidence of amiodarone-related phlebitis at a northern California medical center,
telemetry unit, warrants attention to address such complication. Using the graphic cause and
effect diagram, also known as an “Ishikawa diagram,” the author laid out the possible reasons for
the high incidence of amiodarone-related phlebitis in her microsystem (see appendix B for the
Ishikawa diagram).

With the increasing demands for evidence-based approaches on healthcare practice, it is
important for clinicians to base their decisions on the best available scientific evidence. A key
step in finding answers based on evidence-based practice is framing the clinical question in an
organized manner to find the answer. PICOT is a strategy and is widely used in framing clinical
and research questions, and aids in formulating questions clearly and concisely. First introduced
in 1995 only as PICO, it was eventually expanded by adding the letter “T,” hence, eventually
became known as PICOT (Davies, 2011). The acronym stands for the following: P - patient or
problem, I - intervention, C - comparison, O - outcome, and T - for time. By utilizing this
framework, the author formulated a clinical practice question aimed at improving clinical
practice and patient care in a cardiac microsystem. The formulated question the author designed
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using the PICOT framework for her planned practice improvement is: “In cardiac patients
developing peripheral phlebitis during amiodarone infusion, how does the implementation of
expanded evidence-based-practice (EBP) guideline compared to the current hospital infusion
guidelines will affect the incidence rate of phlebitis over a period of four weeks?” Through
interventions such as educational program and implementation of EBP guideline related to

amiodarone infusion, the author’s expectation is that the incidence rate of phlebitis will decrease
and lead to better patient outcomes.
Specific Aim
By introducing evidence based-change of practice guideline to improve patient care
delivery, the goal is, by August 2018, the implementation of expanded amiodarone infusion
guidelines in a telemetry unit will result in a 20% decrease in the incidence of peripheral
phlebitis related to amiodarone infusion.

Context
The author’s microsystem is a cardiac-driven unit, with a 30-bed capacity, located in
Northern California. It is a multi-specialty unit with the primary focus in caring for patients
needing services ranging from coronary/cardiac interventions, cardiothoracic surgeries, cardiac
device implants, care post myocardial infarction, and care of various cardiac-related symptoms.
The average length of stay of four to five days. Patient-to-nurse ratio is usually 4:1, but changes
to 3:1 when the patient assignment involves recovering patients with post coronary artery
interventions, trans-catheter aortic valve replacements (TAVR), and cardiac ablations (see
Appendix C for microsystem profile). The make-up of employees and patients reflect the city’s
wide demographics of varying cultural backgrounds. Patients and staff are culturally and
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ethnically diverse. The diverse composition of staff is beneficial in delivering culturally-sensitive
care for most patients.
With the primary medical care focus on cardiac-related diagnoses, amiodarone infusion is
a common occurrence in this microsystem. Current hospital infusion guidelines regarding
amiodarone infusion consist of the use of in-line filter, and central line requirement for drug
concentration of 2mg/ml. These guidelines are actively being followed by staff, however, the
incidence rate of phlebitis remains noticeably high, prompting the author to conclude that the
current guideline is insufficient to prevent the occurrence of amiodarone-related phlebitis.
Further intervention is needed to alleviate such a problem.

Intervention and Methods
Quality improvement (QI) methods have been a common trend in healthcare to support
the delivery of quality care that is also timely, safe, and effective, as well as cost efficient. Of the
many QI tools and methods, the Plan-Do-Study-Act (PDSA) cycle is the method for quality
improvement the author has chosen to use for the planned change of practice. The PDSA cycle,
first introduced to Dr. Deming by his mentor, Walter Shewhart of the famous Bell Laboratories
in New York, is a systematic process for acquiring valuable learning and knowledge for the
continual improvement of a product, process, or service (The W. Edwards Deming Institute,
2018).
PDSA method offers the benefit of learning as quickly as possible whether an
intervention works and thus allowing the system to make adjustments accordingly to achieve the
desired improvement (Reed & Card, 2016). Unlike controlled trials, PDSA allows the flexibility
of new learning to be built in to the experimental process where, if problems are identified with
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the original plan, then the theory is easily revisable to fit the new learning and one can then
proceed to test its effectiveness in achieving the planned change. Using this method allows
continual identification of further problems that might need to be addressed. The adaptability of
PDSA is an important feature that is valuable in this current complex state of healthcare systems
where change has become constant (see appendix D for the PDSA cycle for the improvement
project).
The planning stage started with assessment and recognition of the problem in the
microsystem. The author discussed the evident problem with the manager/preceptor and the
planned evidence based-change of practice project plan. The author recruited team members with
varying key roles that consisted of three charge nurses from different shifts, an intravenous
nurse, and a pharmacist. Charge nurses are tasked with assisting the author in disseminating
information to staff on their respective shifts about the planned change in practice. The charge
nurses were assigned to assist in gathering and recording amiodarone infusions and any phlebitis
incidences in a designated log book. The author set up an informational interview with the
intravenous (IV) nurse to discuss intravenous lines, vein anatomic variations and other subjects
related to intravenous therapy. The pharmacist was tasked to serve as an expert for information
regarding amiodarone infusion, facility infusion guidelines, and pharmaceutical-related
prescribing information. The author was responsible for literature searches and designing a
knowledge assessment of staff related to educational program. A Gantt chart was constructed to
provide a detailed timeline of the change in practice project (see appendix E). Together with the
team assembled, the author and team members proceeded to the next phase of PDSA cycle; the
“Do” phase.
Acting on the planned practice change required constant discussions with team members.
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Charge nurses reminded staff during huddles about the improvement projects, and also recorded
demographic information about patients and their amiodarone infusion dates, sites, and gauge
sizes of intravenous catheter used. Most importantly, when patient developed phlebitis, grading
of phlebitis was recorded using the INS phlebitis scale in the log book. The IV nurse
recommended further exploration of INS practice regarding phlebitis management. She assisted
in discussing causes of phlebitis, treatment, and the most current best practice recommendations.
She also discussed ideal locations for intravenous sites, and gauge size of catheter ideal for
infusing acidic substances, such as amiodarone. Her recommendations were consistent and
validated by INS during the author’s literature search.
The Pharmacist provided amiodarone infusion guideline recommendations based on the
pharmaceutical prescribing information, and discussed the current packaging and the
pharmaceutical company used by the hospital as the supplier. The information aided the author
in structuring the literature search and helped narrow the focus to that particular supplier. In
addition, current hospital infusion guidelines were also discussed by the pharmacist with the
author. The author performed literature searches regarding amiodarone infusion, phlebitis, and
extended the search to include amiodarone extravasation. Literature review was performed using
CINAHL, Cochrane, Google Scholar, PubMEd, and 1Findr. The author accessed and reviewed
various guidelines, policy and procedures at her institution related to infusion causing phlebitis
or extravasation. The author was able to establish communication via e-mail with one author,
discussing her published amiodarone infusion guideline (see appendix F) and requested
permission to adapt her published infusion guideline for educational purposes, to which she
graciously agreed. (M. Spiering, personal communication, June 14, 2018).
To accurately gasp the level of knowledge staff have regarding amiodarone infusion, the
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author distributed a baseline amiodarone nursing knowledge assessment (see appendix G for the
knowledge assessment questionnaire). The author then assembled all the information and
prepared an educational poster used to educate staff about amiodarone infusion and phlebitis.
Backed by literature search and EBP, the poster was then used to educate staff and displayed in
the nursing unit for staff viewing and reference. Education was provided to all nursing staff
across three different shifts discussing amiodarone and phlebitis, emphasizing the EBP infusion
guideline implementation shown in the poster, and providing answers and feedback to staff over
the course of several weeks. In addition, the author simultaneously had ongoing discussions with
team members on how to best record and maintain the amiodarone log book in a format that was
easy to access and record information. This format was modified recording according to
feedback from team members and other staff. In addition, the author provided staff assistance in
evaluation of phlebitis incidences on some patients, and seized the opportunity to include
patients in educating them about amiodarone infusion by encouraging their participation in the
prevention of amiodarone-related phlebitis complications. Patients were instructed to notify staff
immediately for any early signs and symptoms of phlebitis, such as pain and redness to infusion
site.
Study of the Intervention
In order to identify whether or not interventions are effective for any process
improvement project, it is important to study the efficacy and potential generalizability of these
interventions for improving practice in healthcare. Continually utilizing the PDSA method for
change of practice project, the letter “S,” which stands for “study”, is appropriately assigned and
can be utilized as a guide for what is next in a sequence of steps in evaluating practice
improvement interventions that were enacted. To study the reliability and effectiveness of
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interventions, the author first measured the baseline nursing knowledge of nursing staff related to
amiodarone infusion before the educational program and guidelines were implemented. The
author then re-measured their knowledge after four weeks of the educational program by using
the same survey questions that were initially distributed at the baseline knowledge assessment.
This measure provides an opportunity to evaluate differences in knowledge acquisition, and
whether or not this will translate to change in nursing practice, which could lead to eventual
decrease in incidence rate of amiodarone-related phlebitis in the microsystem.
Another method in addition to studying and evaluating interventions was to compare the
number of cases of amiodarone-related phlebitis before and after the educational program and
guideline implementation. By comparing the incidence rates, any changes in the phlebitis rate
could be attributed to the interventions that were initiated. however, it can be difficult to
determine whether an improvement in incidence rate is related to guideline implementation, or
due to increased understanding and awareness of the amiodarone side effects on the part of staff;
or both. The result revealed an increased in incidence rate post-interventions. However, it is
important to consider the imbalance in the length of time data collection that was performed. The
discrepancy is due to limitation in time allotted for this improvement project, which only allowed
four weeks to collect data post educational program and guideline implementation due to the
academic deadline set by the educational institution. The author however, has extended the data
collection to go over a six-month period to match the data collection time pre-and postintervention.
The last stage of PDSA cycle, “Act,” required the team to constantly reflect and analyze
the interventions and the results being collected, adjusting the protocols as they saw fit in order
to improve the process. With the tracking of amiodarone-related phlebitis, for example, the log
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book was continuously updated to make it user-friendly for staff to log amiodarone infusions and
phlebitis formation over the course of four weeks. The team provided support and feedback, as
well as reinforced staff education, since initial results post-intervention have remained above
goal. They have also reexamined the process further to identify any opportunities for
improvement. Adjustments have been made to adapt in differences in staff’s learning needs and
style. Ongoing plans to re-evaluate the effectiveness of adjustments are in works. The PDSA
cycle is an ongoing process, making changes as needed to improve the process, with the goal of
staff’s adaptation to process improvements in order to eventually become more efficient as these
improvements slowly become embedded to the microsystem. The success of the planned change
relies on staff compliance once it is implemented. Results of the interventions are discussed
further in the following sections of this manuscript.
Measures
To determine whether or not there were any changes to nursing knowledge regarding
amiodarone and phlebitis, a survey of 56 nursing staff from three different shifts was conducted,
assessing their knowledge regarding amiodarone infusion and phlebitis before and after the
educational program. The questionnaire was designed by the author based on her observations of
the knowledge needed in her microsystem, and what was used in literature in addressing staff’s
knowledge deficit related to amiodarone infusion. The author designed the survey questions
factoring in the current limited hospital guideline in place. The same survey questions were
administered to nursing staff again after the educational program to determine any changes in the
knowledge level of staff regarding amiodarone infusion and phlebitis. Results were then gathered
and broken down into the specific questions that were used in the survey. Baseline nursing staff
knowledge assessment results (see appendix H) were presented in graphical format for ease in
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interpretation. Post-educational program nursing staff knowledge assessment results were also
presented graphically (see appendix I) for consistency in data presentation. The author also
compared the incidence rate of amiodarone related phlebitis before and after the educational
program and with the implementation of infusion guideline. This is to determine whether
knowledge level of staff and implementation of an infusion guideline are factors in any changes
to the incidence rate of phlebitis.
There are no available metrics specific to amiodarone-related phlebitis in the
microsystem. However, the development of phlebitis can affect patient satisfaction, length of
stay due to complication, and cost containment; all considered metrics that matter in any
healthcare industry, including in this microsystem. Benchmarking was performed with other
medical and academic institutions using published literature and studies of the incidence rates,
improvement processes, and outcomes. There is no current national benchmark specific to
amiodarone-related phlebitis, however, INS (2011) has indicated that phlebitis rate in any given
population should only be 5% or less when receiving peripheral infusion.
To identify any improvements, the team collected data after educational program and
guideline implementation, tracking all amiodarone infusions in the microsystem. Data collection
included the following information: patient demographics, medical record number, diagnosis,
amiodarone infusion timeframes, IV sites information, and phlebitis scale utilization. Data
regarding amiodarone infusion and phlebitis incidence rate post-educational program and
guideline implementation were gathered over the course of four weeks. Results were then
compared to data of amiodarone infusion and phlebitis rate incidence collected before
educational program and infusion guideline implementation.
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Analysis/Discussion
Quantitative and qualitative methods were used in the improvement project to obtain the
data necessary to draw conclusions. The survey questions for assessing both baseline and posteducational program nursing knowledge were designed as qualitative measures, but, in order to
analyze the answers more easily, a numerical value was assigned and made the analysis
quantifiable. The graphical representation and display of the results were another method of
presenting the data quantitatively. In addition, a multiple-choice question was utilized to select
an answer that best described the nursing staffs’ preference involving infusion site and IV gauge.
The data collected regarding the rate of phlebitis incidence prior to educational program and
guideline implementation were collected over a period of six months. This data showed a 40%
rate of amiodarone related phlebitis. On the other hand, the data collected post-educational
program and guideline implementation was only over a period of 4 weeks, and showed a 43%
incidence rate of phlebitis. The result revealed a higher incidence, opposite of the goal of lower
incidence. It is however too early and premature to drew a final conclusion of the interventions’
effectiveness, since the data collection was done on a very short time after the interventions were
initiated, and sample population is still small. An outcomes study is in progress and an analysis
of the true effectiveness of the study is pending.

Ethical Considerations
Ethics Approval
The study was done without approval from the Medical Center’s Institutional Review
Board (IRB). Patient confidentiality was maintained and protected using medical record
numbers, diagnosis, and other demographics-related information as identifiers.
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Results
The educational program for nursing staff and implementation of EBP infusion guideline
related to amiodarone resulted in increased understanding of nursing staff. However, the
incidence rate of phlebitis remained high and above goal, and is not reflected in the early results
of the study. The incidence rate pre-interventions were collected over a six-month period,
showing a 40% versus over four-weeks post-interventions showing a 43% phlebitis incidence
rate. It is however, important to note that the initial result is not a true indication of the
effectiveness of the interventions, due to time limitation in data collection post-intervention and
sample size of the population. The author has extended the data collection to go over a six-month
period. The ability to draw a balanced comparison and to arrive at a final conclusion are not
possible at this time. An outcomes evaluation will be made six months after the interventions
were enacted to truly assess the effectiveness of the quality improvement project.
Summary
A key to resolving the high incidence of amiodarone-related phlebitis is the utilization of
EBP standards and addressing knowledge deficits of staff. By increasing knowledge and utilizing
EBP guideline, the goal was to promote early detection, apply knowledge learned, and encourage
vigilance in monitoring IV sites during infusion. The author is confident that the educational
program and the implementation of amiodarone infusion best practice remains the key to
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resolving high incidence of phlebitis in her microsystem. Although the initial result has not
shown any impact in lowering the incidence, the author believes that eventually, the

interventions will be successful, and will be reflected in the final outcomes study that is currently
pending. By slowly introducing staff and immersing them to EBP approaches, improvement
project can be successful and can only lead to a better health outcome.
Interpretation
After implementation of quality improvement interventions, initially, the incidence rate
of phlebitis remained high. Similar studies reported that an improvement in phlebitis rate when
implementation of infusion guidelines and staff education were adopted. Others have made
successful similar efforts after recognizing the problem, while others have adopted changes in
their practice protocol with outcome study pending at the time of publication. Knowledge of
staff regarding amiodarone infusion in the microsystem improved, as was reflected in their post
educational survey results. However, improved knowledge did not equate to a lower phlebitis
rate, at of this writing. On the other hand, the final outcome cannot be analyzed fully until six
months of data has been collected to see whether the interventions were truly effective. The
engagement and the sustainability of staff compliance with the infusion guideline will also be a
factor that will be determined over time. If successful, replication of the improvement project
processes can be instituted at other cardiac-focused units.
Limitations
Initial results in this quality improvement project are not comparable to pre-intervention
data due to the unequal time in data collection after implementation of intervention. The sample
size is small and the length of time for data collection is very short. An effort to extend the data
collection over six-month period is in progress to determine the real impact of the intervention
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and evaluate the outcome of study. Another possible limitation to the study is distinguishing

whether any improvement in the trend of phlebitis incidence in the future is a direct result of the
infusion guideline implementation, or a result of increase awareness of staff about the sideeffects of amiodarone infusion. However, it is also possible that it could be related to both
reasons. The result of the project is limited and not generalizable beyond the adult cardiac
population.
Conclusion
Managing amiodarone-related phlebitis poses a challenge in a cardiac-focused
microsystem. The frequency of using amiodarone to manage arrhythmias continues, and the need
to control the high incidence of amiodarone-related phlebitis remains pervasive. Attempts to
alleviate such issues have been addressed, and the nursing profession is instrumental in
attempting to find solutions to decrease the incidence, as evidence by the availability of multiple
published nursing-led research addressing the issue. Nurses are in key positions to detect,
educate, and intervene when there is an obvious breakdown in care management affecting the
delivery of quality care. The nursing profession has evolved over time, and nursing research
focusing on the delivery of quality care based on evidence based-practice is the trend specific to
nursing in healthcare.
In response to quality care issues, a role was created in the nursing profession; the clinical
nurse leader (CNL). The nursing role most suited for improvement project is that of a CNL. A
CNL may serve as a point-of-care clinician, outcomes manager, risk anticipator, and as an
educator just to name a few of the roles. An evidenced based change-in-practice project such as
decreasing the incidence of peripheral phlebitis related to amiodarone infusion, is the type of
improvement project for which the CNL role was created. The nursing implications for an
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evidence-based project like this is that it can be replicated by any telemetry nursing unit looking
to improve patient outcomes related to amiodarone infusion, and can ultimately contribute to
improved quality of care, greater patient satisfaction, and decreased healthcare costs.
As nurses are on the frontline in healthcare delivery, it can be argued that they make the
biggest impact in patient care. Improvement projects such as addressing phlebitis incidence in
collaboration with a CNL and other multi-disciplinary team is providing quality nursing care.
The current healthcare climate is driven by quality measures and since payments are increasingly
tied to performance, providing quality care has become the focus of every healthcare
organization. Quality care and EBP have now become synonymous, and therefore, the utilization
of CNL skills will likely expand in the future. The roles specific for CNL are aligned with the
goals and direction of the healthcare industry in general.
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Appendix A
Types of Phlebitis

Figure A1. Adapted from Infusion Nurses Society. (2016) Infusion therapy standards of practice.
Journal of Infusion Nursing, 39, (1S), 95-10. Copyright 2016 by Infusion Nurses Society.
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Appendix B
CAUSES OF AMIODARONE-RELATED PERIPHERAL PHLEBITIS
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Figure B1. Ishikawa Diagram: Factors contributing to the development of high
incidence of amiodarone-related peripheral phlebitis in a cardiac-focused. .
microsystem

Amiodaronerelated
peripheral
phlebitis
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Appendix C
The Cardiac Microsystem Profile

Note. Inpatient Unit Profile. Adapted from The Dartmouth Institute. (2018). Clinical
microsystems. Retrieved from http://clinicalmicrosystem.org/knowledge-center/workbooks.
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Appendix D
The PDSA Cycle

Figure D1. Quality improvement method used for a change-in practice project related to
amiodarone infusion causing high incidence of phlebitis in a cardiac-driven unit.
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Appendix E
Gantt Chart
GANTT CHART: CHANGE IN PRACTICE PROJECT TO DECREASE INCIDENCE OF PERIPHERAL AMIODARONE PHLEBITIS

Week 1

Week 2

Week 3

Week 4

Week 5

Week 6

Week 7

Week 8

Week 9

Week 10

PLANNING
Microsystem Reassessment, Discussed
planned project with preceptor, day shift
staff. Team building: met with charge
nurses all 3 shifts, IV nurse, and
pharmacist. Reviewed guideline and
policy.
Literature review, revised SOD, discussed
project with day/ pm/noc shift staff.
Baseline survey of staff’s knowledge of
amiodarone.
Literature review, e-mailed 3 published
authors related to amiodarone phlebitis.
Updated preceptor, team building, met
with PICC line /IV nurse. Collection of
baseline knowledge continues. Create a
log book for tracking infusion/ phlebitis.
Review expanded EBP guideline with
team.
IMPLEMENTATION:
Provide education to staff every shift.
Provide feedback. Discuss timeline for
project. New guideline implementation.
Start tracking infusion/phlebitis. Ongoing
discussion with team members and
preceptor. Monitor log book and
implementation. Involve patient with
education.
EVALUATION/DATA ANALYSIS:
Meet with team members. Reassessed
knowledge of staff. Distribute the same
survey questions collected for baseline
knowledge. Compare current knowledge
to baseline data. Compare incidence rate
of phlebitis pre and post guideline
implementation. Discuss trends with
team member, staff and preceptor.
Write Final N653 Paper
Prepare Poster Presentation
Present Poster at USF

Figure E1. Change in practice project timeline to decrease the incidence of peripheral
amiodarone-related phlebitis in a cardiac-driven unit.

Week 11

Week 12
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Appendix F
Guideline for Peripheral Amiodarone Infusion
1. USE DEDICATED LINE
a. No other medication is injected or infusing with amiodarone
b. Always have two lines. One for amiodarone and one for other medications the
patient may need
2. ASSESS THE IV PRIOR TO INFUSION
a. Assess for pain, redness, and assure an adequate flush with 10ml of NS
b. If any issues, document infiltration and phlebitis scale
c. Use the smallest catheter possible in the largest vein
d. Never use an area of joint flexion
e. Use a catheter stabilization device, such as Statlock
3. USE A SEPARATE FILTER FOR AMIODARONE BOLUS AND INFUSION
4. CHECK THE SITE AFTER BOLUS, AND REMOVE THE IV FOR PAIN
5. INSTRUCT PATIENT TO IMMEDIATELY NOTIFY RN FOR ANY PAIN,
REDNESS, OR OTHER CHANGES
a. Remove the IV at FIRST sign of pain (does NOT have to be red to begin vein
irritation)
b. Continue the infusion through a different IV catheter
6. INCLUDE THE IV SITE INSPECTION (not just the drip) DURING CHANGE OF
SHIFT REPORT
7. AT FIRST SIGN OF PAIN, REDNESS, INFILTRATION OR PHLEBITIS, ASPIRATE
AS MUCH MEDICATION FROM THE CATHETER AS POSSIBLE, THEN
DISCONTINUE IV
a. Clean area with CHG
b. Apply ice pack
c. Elevate the affected arm.
d. Document using Infusion Nurses Society approved phlebitis scale
Note. Adapted with permission from Mary Spiering MN, RN, CNS, Professional Practice Program
Manager. Magnet Program Director Nursing Administration, Kaiser Westside Medical Center,
Hillsboro, Oregon. The study was completed at Providence Saint Vincent Medical Center, where
she was previously employed.
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Survey Questions Used in Assessment of Nursing Staff knowledge
NURSING STAFF KNOWLEDGE ASSESSMENT RELATED TO AMIODARONE INFUSION:
SCALE:
1= Poor
2= Below Average
3= Average
4= Above Average
5= Outstanding

Please rate your knowledge on a scale of 1 to 5 as above:
A.
1. What is your knowledge regarding the drug Amiodarone?
2. How familiar are you with the possible side effects of peripheral amiodarone infusion?
3. What is your knowledge of the rate, dosing, and set up of intravenous amiodarone
infusion?
4. Your knowledge of Infusion Nurses Society phlebitis scale?
5. Your knowledge of different causes/ types of phlebitis?
6. What is your knowledge on how to treat phlebitis?
7. What is your understanding of the length of time it takes for phlebitis to appear?

B. WHICH IV SITE DO YOU PREFER TO INFUSE THE AMIODARONE DRIP? (circle one answer)
a. 18 gauge, large vein
b. 18 gauge, small vein

c. 22 gauge, small vein
d. 22 gauge, large vein

Appendix H
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Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion
(Before
Program)
COMBINED RESULTS
OFEducational
ALL 3 SHIFTS
RESPONDENTS
1. What is your knowledge regarding the drug amiodarone?

1

18%
34%

2
3
4

48%

5

Figure H1. Breakdown results of nursing staff baseline knowledge assessment related to
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are:
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix H
Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion
(Before Educational Program)

COMBINED RESULTS OF ALL 3 SHIFTS RESPONDENTS
2. How familiar are you with the possible side effects of peripheral

amiodarone infusion?
2%

1

18%
32%

2
3
4

48%

5

Figure H2. Breakdown results of nursing staff baseline knowledge assessment related to
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are:
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix H
Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion
(Before Educational Program)

COMBINED RESULTS OF ALL 3 SHIFTS RESPONDENTS
3. What is your knowledge of the rate, dosing, and set up of IV

amiodarone infusion?
4%

16%

1
2

39%

3
4
41%

5

Figure H3. Breakdown results of nursing staff baseline knowledge assessment related to
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are:
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix H
Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion
(Before Educational Program)

COMBINED RESULTS OF ALL 3 SHIFTS RESPONDENTS
4. What is your knowledge of Infusion Nurses Society phlebitis

scale?

11%

5%

23%

1
2
3

23%

4
38%

5

Figure H4. Breakdown results of nursing staff baseline knowledge assessment related to
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are:
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix H
Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion
(Before Educational Program)

COMBINED RESULTS OF ALL 3 SHIFTS RESPONDENTS
5. What is your knowledge of the different causes/types of

phlebitis?

18%

2%

14%

1
2
3

21%

4
45%

5

Figure H5. Breakdown results of nursing staff baseline knowledge assessment related to
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are:
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix H
Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion
(Before Educational Program)

COMBINED RESULTS OF ALL 3 SHIFTS RESPONDENTS
6. What is your knowledge on how to treat phlebitis?

2%

18%

1
2
44%

36%

3
4
5

Figure H6. Breakdown results of nursing staff baseline knowledge assessment related to
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are:
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix H
Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion
(Before Educational Program)

COMBINED RESULTS OF ALL 3 SHIFTS RESPONDENTS
What is your understanding of the length of time it takes for
phlebitis to appear?

11%

5%
18%

27%

1
2
3
4

39%

5

Figure H7. Breakdown results of nursing staff baseline knowledge assessment related to
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are:
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix H
Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion
(Before Educational Program)

Which IV site do you prefer for infusion of amiodarone?

22 GA, LG VEIN

6

22 GA, SM VEIN

1

18 GA, SM VEIN

5

18 GA, LG VEIN
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Figure H8. Breakdown result of nursing staff baseline assessment of their preferred intravenous
(IV) gauge size, and site when infusing amiodarone.
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Appendix I
Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to
Amiodarone Infusion

1.What is your knowledge regarding the drug amiodarone?

9%
1
2

43%

3
4

48%

5

Figure I1. Breakdown results of nursing staff knowledge reassessment related to
amiodarone infusion based on the designated question. Scale rating of knowledge
equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix I
Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to
Amiodarone Infusion

2. How familiar are you with the possible side effects of
peripheral amiodarone infusion?

7%
1
2

43%

3

50%

4
5

Figure I2. Breakdown results of nursing staff knowledge reassessment related to
amiodarone infusion based on the designated question above. Scale rating of knowledge
equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix I
Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to
Amiodarone Infusion

3. What is your knowledge of the rate, dosing and set of IV
amiodarone?

7%
1
2

48%

3

45%

4
5

Figure I3. Breakdown results of nursing staff knowledge reassessment related to
amiodarone infusion based on the designated question above. Scale rating of knowledge
equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix I
Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to
Amiodarone Infusion

4. What is your knowledge of the Nurses' Society phebilits
scale?

7%
30%

1

25%

2
3
4
5

38%

Figure I4. Breakdown results of nursing staff knowledge reassessment related to
amiodarone infusion based on the designated question above. Scale rating of knowledge
equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix I
Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to
Amiodarone Infusion

5.What is your knowledge of the different causes/types of
phlebitis?

0%
2%

12%
1

38%

2
3
4

48%

Figure I5. Breakdown results of nursing staff knowledge reassessment related to
amiodarone infusion based on the designated question above. Scale rating of
knowledge equivalent are: 1=poor, 2=below average, 3=average, 4=above average,
5=outstanding.
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Appendix I
Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to
Amiodarone Infusion

6. What is your knowledge of how to treat phlebitis?

18%
1

37%

2
3
4
5

45%

Figure I6. Breakdown results of nursing staff knowledge reassessment related to
amiodarone infusion based on the designated question above. Scale rating of knowledge
equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix I
Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to
Amiodarone Infusion

7. What is your understanding of the length of time it takes for
phlebitis to appear?

11%
1
2

41%

3
4

48%

Figure I7. Breakdown results of nursing staff knowledge reassessment related to
amiodarone infusion based on the designated question above. Scale rating of knowledge
equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 5=outstanding.
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Appendix I
Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to
Amiodarone Infusion

Which IV site do you prefer for infusion of amiodarone?

22 GA, LG VEIN
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Figure I8. Breakdown result of nursing staff reassessment of their preferred intravenous (IV)
gauge size, and site when infusing amiodarone.
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